dart4mm: daratumumab in myeloma patients with vgpr to first-line therapy
Published 3 years ago • 170 plays • Length 2:09Download video MP4
Download video MP3
Similar videos
-
2:42
final results of the dart4mm study of daratumumab for mrd eradication in myeloma
-
2:30
daratumumab and isatuximab in the treatment of multiple myeloma
-
5:07
daratumumab in the management of al amyloidosis
-
1:44
trimm-2: talquetamab daratumumab in patients with r/r multiple myeloma
-
4:13
daratumumab as maintenance therapy after autosct in patients with multiple myeloma
-
0:52
the future of daratumumab in multiple myeloma
-
3:57
daratumumab in the treatment of mm with high-risk cytogenetics
-
4:38
the potential of mrd-adapted treatment in multiple myeloma
-
26:47
how to become a hematology oncologist
-
13:43
darzalex® iv (daratumumab) mechanism of action for multiple myeloma
-
1:26
adverse events associated with btkis in the treatment of waldenström’s macroglobulinemia
-
1:42
wm-net: upcoming clinical trials to advance the treatment of wm
-
1:48
a phase ii study of daratumumab and pomalidomide in previously treated patients with al amyloidosis
-
4:22
optimizing treatment sequencing in multiple myeloma: daratumumab upfront versus subsequent lines
-
3:15
addition of daratumumab to r/r myeloma regimens improves outcomes
-
4:01
choosing between isatuximab & daratumumab in multiple myeloma
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
1:20
mrd in myeloma
-
1:04
revolutionizing mm treatment with daratumumab
-
1:26
insight-mm study update: treatment patterns in first and second-line multiple myeloma
-
1:50
molecular characteristics of extramedullary myeloma
-
0:52
phase i study of ft538, an ipsc-derived nk cell therapy, with daratumumab in r/r multiple myeloma